ep miss lower org growth
end organ growth guid trim
organ growth vs cs estimate sale bil
mil estim mil consensu
ep in-lin estim street sale net cog
partial off-set lower sg lower tax oper
margin roughli line
guidanc organ sale growth guidanc
previous ep guid vs previous
compar estim includ accret btg
factset consensu
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
boston scientif corp global manufactur provid
medic devic equip area vascular intervent
structur heart men women health
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
one-year valuat scenario base
ev/ebitda ebitda bil
scenario base emerg segment deliv
growth high-growth segment grow growth
grow
one-year valuat grey scenario base
ev/ebitda grey ebitda bil
grey scenario base emerg segment deliv
growth high-growth segment grow growth
grow
 close
sale
sale
estimate
ep
sale
sale
estimate
charl martineau pm univers toronto compani mention price
